25 related articles for article (PubMed ID: 38430581)
1. Maternal Di-(2-ethylhexyl)-Phthalate exposure during pregnancy altered energy metabolism in immature offspring and caused hyperglycemia.
Huang B; Zhang N; Wang J; Gao Y; Wu W; Jiang M; Han M
Ecotoxicol Environ Saf; 2024 Jul; 279():116494. PubMed ID: 38820878
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.
Suk FM; Liu CL; Hsu MH; Chuang YT; Wang JP; Liao YJ
Sci Rep; 2019 Nov; 9(1):17259. PubMed ID: 31754201
[TBL] [Abstract][Full Text] [Related]
3. Plasticizer Di-(2-Ethylhexyl)Phthalate Induces Epithelial-to-Mesenchymal Transition and Renal Fibrosis In Vitro and In Vivo.
Wu CT; Wang CC; Huang LC; Liu SH; Chiang CK
Toxicol Sci; 2018 Jul; 164(1):363-374. PubMed ID: 29669060
[TBL] [Abstract][Full Text] [Related]
4. Dissimilar patterns of promotion by di(2-ethylhexyl)phthalate and phenobarbital of hepatocellular neoplasia initiated by diethylnitrosamine in B6C3F1 mice.
Ward JM; Rice JM; Creasia D; Lynch P; Riggs C
Carcinogenesis; 1983 Aug; 4(8):1021-9. PubMed ID: 6872148
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
6. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
Xu Y; Xu H; Li M; Wu H; Guo Y; Chen J; Shan J; Chen X; Shen J; Ma Q; Liu J; Wang M; Zhao W; Hong J; Qi Y; Yao C; Zhang Q; Yang Z; Qian C; Li J
Cancer Lett; 2019 Jul; 454():78-89. PubMed ID: 30980868
[TBL] [Abstract][Full Text] [Related]
7. Long-term di-(2-ethylhexyl) phthalate exposure reduces sorafenib treatment efficacy by enhancing mesenchymal transition in hepatocellular carcinoma.
Shih MS; Suk FM; Chiu WC; Lee CY; Hsu FY; Liao YJ
Ecotoxicol Environ Saf; 2024 Mar; 273():116161. PubMed ID: 38430581
[TBL] [Abstract][Full Text] [Related]
8. The impact of Di-(2-ethylhexyl) Phthalate and Mono(2-ethylhexyl) Phthalate in placental development, function, and pathophysiology.
Martínez-Razo LD; Martínez-Ibarra A; Vázquez-Martínez ER; Cerbón M
Environ Int; 2021 Jan; 146():106228. PubMed ID: 33157377
[TBL] [Abstract][Full Text] [Related]
9. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
11. Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk.
Huber WW; Grasl-Kraupp B; Schulte-Hermann R
Crit Rev Toxicol; 1996 Jun; 26(4):365-481. PubMed ID: 8817083
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic considerations for human relevance of cancer hazard of di(2-ethylhexyl) phthalate.
Rusyn I; Corton JC
Mutat Res; 2012; 750(2):141-158. PubMed ID: 22198209
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
